Hub : Traits :

Crohns Disease (2017)

1366 significantly associated models · 266 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	7314655	8738937	2	1	2.3e-08	7.4e-08	3.8e-06	26	PARK7
2	1	66304567	68152438	4	5	1.6e-69	5.8e-97	9.0e-25	76	IL23R MIER1
3	1	113751640	115152814	1	1	1.1e-08	6.4e-16	1.6e-09	44	DCLRE1B
4	1	154325302	156572984	16	1	2.5e-11	6.8e-09	4.0e-01	98	ADAM15
5	1	160559549	161098128	2	1	1.7e-07	3.7e-08	3.7e-03	72	ITLN1
6	2	24324172	25837917	3	1	1.0e-13	2.6e-11	8.8e-01	100	ADCY3
7	2	26883355	29344127	3	2	5.2e-12	6.3e-11	9.7e-01	100	AC074117.10 RP11-373D23.3
8	2	42753863	44157441	2	1	4.0e-09	1.5e-11	9.2e-05	66	AC010883.5
9	2	60466491	62107632	5	1	7.2e-13	5.9e-14	1.5e-02	90	PEX13
10	2	101981794	103767612	4	2	7.3e-13	1.6e-13	1.0e+00	100	IL18R1 IL1RL1
11	2	197976089	200117777	1	1	5.9e-08	5.0e-08	1.5e-01	93	PLCL1
12	2	230396934	231875433	1	1	8.6e-08	2.8e-14	2.5e-08	46	SP140
13	2	233227833	235170697	5	2	5.4e-61	1.8e-62	1.0e+00	100	ATG16L1 SCARNA5
14	3	47911521	50921261	29	1	4.9e-26	4.6e-24	3.4e-02	96	MST1
15	3	52242902	53860103	2	1	4.6e-09	7.9e-09	3.0e-01	97	RFT1
16	3	140350567	141867638	1	1	1.1e-07	3.1e-08	1.0e+00	100	ZBTB38
17	4	122377715	123976639	1	1	3.6e-08	2.4e-08	1.7e-01	94	KIAA1109
18	5	39986432	41555158	4	3	1.2e-20	8.3e-56	2.8e-28	51	CARD6 PRKAA1 PTGER4
19	5	95519506	97065386	3	1	4.7e-15	5.1e-15	1.0e+00	100	ERAP2
20	5	129797129	132900729	17	6	1.1e-33	5.6e-36	NaN	NaN	HINT1 PDLIM4 SLC22A5
21	5	140789933	142230251	1	1	1.5e-12	4.1e-12	3.4e-01	98	NDFIP1
22	5	149577574	151236214	6	1	1.3e-21	2.1e-20	3.9e-02	95	DCTN4
23	5	158501850	159005439	1	1	1.2e-18	7.5e-22	1.2e-04	84	IL12B
24	6	127196109	127764305	1	1	2.7e-07	1.8e-09	1.4e-03	72	RSPO3
25	6	166651581	167841508	4	1	4.5e-23	3.7e-22	3.1e-02	95	RNASET2
26	7	99591418	100979310	1	1	4.6e-08	5.0e-06	8.4e-02	86	GIGYF1
27	9	108998	1162143	1	1	2.9e-07	6.0e-07	6.6e-01	99	DOCK8
28	9	4287179	5824205	2	1	3.7e-14	1.6e-16	1.0e-03	84	IGHEP2
29	9	116849447	118389134	2	2	4.3e-21	1.8e-21	4.6e-02	96	TNFSF15 TNFSF8
30	9	138525778	140321666	10	3	1.2e-28	3.1e-30	1.0e+00	100	CARD9 RP11-611D20.2
31	10	30028267	31432776	1	1	4.1e-08	1.9e-11	2.2e-05	60	MAP3K8
32	10	34607015	36198981	2	1	8.6e-15	6.3e-15	1.0e+00	100	CUL2
33	10	63856856	65264300	3	1	1.7e-17	5.5e-29	3.9e-14	54	ADO
34	10	74714177	76323150	13	1	1.8e-11	6.0e-11	3.4e-03	80	RP11-464F9.22
35	10	80130592	82984432	2	2	5.3e-15	8.9e-15	3.0e-05	71	TSPAN14 ZMIZ1
36	11	63316786	64820283	2	1	1.9e-08	3.2e-07	2.2e-01	94	PPP1R14B
37	11	64954053	66333072	1	1	2.0e-07	2.0e-06	1.0e-02	71	FIBP
38	11	75457950	77069746	2	2	1.1e-13	4.7e-24	1.9e-10	60	C11orf30 LRRC32
39	12	39904158	41454590	1	2	2.8e-11	6.1e-21	3.6e-09	60	LRRK2
40	13	43756650	45157394	1	1	3.3e-12	1.4e-13	1.0e+00	100	LACC1
41	14	87606646	89154624	2	3	7.6e-10	2.0e-12	3.5e-01	98	GALC GPR65
42	15	66662107	68183665	1	2	1.2e-14	2.4e-19	8.1e-05	81	SMAD3
43	16	10646170	12426645	2	1	8.4e-11	2.8e-08	9.1e-02	91	RMI2
44	16	27655848	30141258	24	1	9.6e-15	6.9e-13	2.8e-01	98	NFATC2IP
45	16	49403920	51535063	8	11	3.3e-78	1.8e-108	NaN	NaN	ADCY7 BRD7 CYLD HEATR3 NKD1 NOD2 RP11-429P3.3
46	17	25295032	26643541	1	1	4.3e-08	1.5e-09	5.2e-03	79	KSR1
47	17	36710513	39048774	15	1	3.7e-19	5.1e-19	1.3e-02	92	PNMT
48	17	39328012	41699963	7	2	3.8e-12	1.8e-12	2.0e-02	89	NAGLU PTRF
49	18	12538482	13133577	1	1	8.1e-21	1.4e-17	9.6e-01	100	PTPN2
50	19	388413	1802433	3	8	5.1e-16	9.1e-21	NaN	NaN	GPX4 POLR2E
51	19	9829303	11376675	3	2	3.7e-10	2.8e-13	9.4e-11	21	CDKN2D PDE4A
52	19	46157004	47589895	1	1	4.6e-08	3.6e-07	1.0e+00	100	PPP5C
53	19	48464978	49935001	3	1	1.6e-11	2.3e-11	1.0e+00	100	FUT2
54	19	58389355	59095126	1	1	1.4e-07	4.6e-06	4.7e-02	81	RPL23AP79
55	20	43825556	45456440	3	2	3.7e-09	1.3e-09	3.0e-02	87	CD40 MMP9
56	20	61522825	62912463	11	1	2.9e-15	2.7e-13	3.7e-03	84	STMN3
57	21	15634304	17135372	1	1	1.3e-08	2.7e-27	2.2e-20	27	NRIP1
58	21	34077531	35561665	2	2	2.4e-07	1.1e-14	1.8e-03	84	DNAJC28 IFNGR2
59	21	44948764	46443886	2	1	3.2e-14	2.0e-19	2.2e-07	67	ICOSLG
60	22	21075537	22685340	5	1	3.4e-16	6.3e-16	1.0e+00	100	CCDC116
61	22	29585080	31118395	1	1	2.7e-08	4.2e-07	1.9e-01	93	MTMR3
62	22	36500899	37910395	2	1	4.9e-10	1.8e-08	4.9e-01	98	NCF4
63	22	38719189	40529415	3	2	1.1e-15	7.7e-21	8.8e-09	62	APOBEC3D SYNGR1

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Crohns Disease (2012)	21.34	59	37	82.2	0.99	1.2e-64	ADAM15 ADCY3 ADCY7 ADO ATG16L1 BRD7 CARD6 CCDC116 CUL2 CYLD DCTN4 ERAP2 FUT2 GALC HINT1 ICOSLG IGHEP2 IL12B IL18R1 IL1RL1 IL23R LACC1 LRRC32 LRRK2 MIER1 MST1 MTMR3 NAGLU NCF4 NDFIP1 NFATC2IP NKD1 NOD2 PDE4A PDLIM4 PEX13 PLCL1 PNMT PPP1R14B PRKAA1 PTGER4 PTPN2 PTRF RFT1 RMI2 RNASET2 RP11-373D23.3 RP11-464F9.22 RPL23AP79 RSPO3 SCARNA5 SLC22A5 SMAD3 STMN3 SYNGR1 TNFSF15 TNFSF8 TSPAN14 ZMIZ1
Irritable Bowel Disease (IBD)	20.38	73	59	131.1	0.98	8.2e-65	AC010883.5 AC074117.10 ADAM15 ADCY3 ADCY7 ADO APOBEC3D ATG16L1 BRD7 C11orf30 CARD9 CCDC116 CD40 CDKN2D CUL2 CYLD DCTN4 DOCK8 ERAP2 FIBP FUT2 GALC GIGYF1 GPR65 GPX4 HINT1 ICOSLG IGHEP2 IL12B IL18R1 IL1RL1 IL23R ITLN1 KIAA1109 LACC1 LRRC32 LRRK2 MAP3K8 MIER1 MMP9 MST1 MTMR3 NAGLU NDFIP1 NFATC2IP NKD1 NOD2 NRIP1 PARK7 PDE4A PDLIM4 PEX13 PNMT POLR2E PPP1R14B PPP5C PTGER4 PTPN2 PTRF RMI2 RNASET2 RP11-373D23.3 RP11-464F9.22 RP11-611D20.2 RPL23AP79 SCARNA5 SLC22A5 SMAD3 STMN3 SYNGR1 TNFSF15 TSPAN14 ZMIZ1
Ulcerative Colitis (UC)	7.51	26	13	28.9	0.94	6.3e-14	ADO C11orf30 CARD9 CCDC116 ICOSLG IGHEP2 IL12B IL23R KIAA1109 LRRC32 MST1 MTMR3 NAGLU NFATC2IP NRIP1 PARK7 PEX13 PNMT PTPN2 PTRF RP11-611D20.2 SLC22A5 SMAD3 STMN3 SYNGR1 TNFSF15
Ulcerative Colitis	6.45	17	8	17.8	0.94	8.7e-09	BRD7 CARD9 CUL2 ICOSLG IGHEP2 IL12B IL23R LRRK2 MST1 PARK7 PEX13 PNMT PTRF SLC22A5 STMN3 SYNGR1 TNFSF15
Blood Eosinophil Count	6.07	28	22	48.9	-0.09	6.3e-01	AC010883.5 ADCY3 ADO C11orf30 CARD9 CCDC116 CUL2 ERAP2 GIGYF1 GPR65 GPX4 HINT1 IGHEP2 IL1RL1 KIAA1109 LRRC32 NCF4 NDFIP1 PDLIM4 POLR2E PPP5C PTPN2 RFT1 SLC22A5 SMAD3 SP140 TNFSF15 TNFSF8
Allergy	5.71	17	10	22.2	-0.38	9.0e-02	C11orf30 CCDC116 HINT1 IGHEP2 KIAA1109 LRRC32 NCF4 NDFIP1 PDLIM4 PEX13 PLCL1 PNMT RP11-373D23.3 SLC22A5 SMAD3 STMN3 ZBTB38
Asthma	5.63	9	7	15.6	0.18	5.7e-01	CUL2 KIAA1109 LACC1 LRRC32 NDFIP1 PDLIM4 PNMT SLC22A5 SMAD3
Asthma (self-reported)	5.60	11	7	15.6	0.18	5.3e-01	CUL2 HINT1 KIAA1109 LACC1 LRRC32 NCF4 NDFIP1 PDLIM4 PNMT SLC22A5 SMAD3
Respiratory disease	5.52	9	7	15.6	0.17	5.8e-01	KIAA1109 LACC1 LRRC32 NCF4 NDFIP1 PDLIM4 PNMT SLC22A5 SMAD3
Allergy or Eczema	5.11	18	13	28.9	0.72	5.0e-04	AC010883.5 AC074117.10 C11orf30 CCDC116 IGHEP2 KIAA1109 LRRC32 NAGLU NDFIP1 NFATC2IP PEX13 PLCL1 PNMT PTGER4 RP11-373D23.3 SMAD3 STMN3 ZBTB38
Hayfever, allergic rhinitis or eczema	5.06	18	12	26.7	0.62	3.6e-03	AC010883.5 AC074117.10 C11orf30 CCDC116 IGHEP2 KIAA1109 LRRC32 NAGLU NDFIP1 PEX13 PLCL1 PNMT PTGER4 RP11-373D23.3 SLC22A5 SMAD3 STMN3 ZBTB38
Triglycerides	3.99	3	2	4.4	0.00	1.0e+00	AC074117.10 MMP9 RP11-373D23.3
Hypothyroidism (self reported)	3.98	12	6	13.3	0.00	9.9e-01	BRD7 DCLRE1B DNAJC28 FUT2 GIGYF1 MTMR3 NRIP1 PPP1R14B PTPN2 PTRF RNASET2 ZMIZ1
Blood White Count	3.60	24	18	40.0	-0.03	8.9e-01	AC074117.10 ADCY3 ADO CARD9 CCDC116 CDKN2D DCLRE1B ERAP2 GPX4 HEATR3 HINT1 NDFIP1 PDE4A PDLIM4 PEX13 PNMT POLR2E RFT1 RNASET2 RP11-373D23.3 RP11-429P3.3 SLC22A5 STMN3 TSPAN14
Rheumatoid Arthritis	3.51	4	3	6.7	-0.60	4.0e-01	CD40 DCLRE1B PNMT PTPN2
Hypothyroidism/myxoedema (self-reported)	3.43	8	3	6.7	-0.20	6.3e-01	BRD7 DCLRE1B GIGYF1 MTMR3 PPP1R14B PTRF RNASET2 ZMIZ1
Hayfever/allergic rhinitis (self-reported)	3.25	6	3	6.7	0.70	7.9e-02	C11orf30 KIAA1109 LRRC32 PLCL1 PNMT SMAD3
Medication: Levothyroxine sodium	3.10	6	2	4.4	-0.13	8.0e-01	BRD7 DCLRE1B GIGYF1 PTPN2 PTRF RNASET2
Comparative body size at age 10	3.07	4	2	4.4	0.52	4.8e-01	ADCY3 FUT2 NFATC2IP PLCL1
Height	2.92	25	21	46.7	0.34	5.8e-02	AC010883.5 AC074117.10 ADCY3 ADO APOBEC3D ATG16L1 C11orf30 CARD9 CCDC116 FUT2 GPX4 HINT1 IL18R1 IL23R MIER1 MTMR3 PARK7 PDE4A PDLIM4 POLR2E PTRF RFT1 RP11-373D23.3 SLC22A5 ZBTB38
Standing height	2.90	16	10	22.2	0.44	4.7e-02	AC074117.10 ADCY3 ADO CARD9 CCDC116 FUT2 HINT1 MIER1 MTMR3 PDE4A PDLIM4 PTRF RFT1 RP11-373D23.3 SLC22A5 ZBTB38
Medication: Ventolin 100micrograms inhaler	2.69	5	2	4.4	0.51	3.0e-01	KIAA1109 LRRC32 NDFIP1 PNMT SMAD3
Comparative height size at age 10	2.51	13	11	24.4	0.57	1.8e-02	AC010883.5 AC074117.10 ADCY3 CARD9 CCDC116 FUT2 HINT1 MTMR3 NFATC2IP PDLIM4 RFT1 SLC22A5 ZBTB38
Sitting height	2.39	16	10	22.2	0.30	2.3e-01	AC074117.10 ADCY3 ADO CARD9 CCDC116 DCTN4 FUT2 GPX4 HINT1 MIER1 MTMR3 PDLIM4 PPP1R14B RFT1 SLC22A5 ZBTB38
Mouth/teeth dental problems: Mouth ulcers	2.33	4	2	4.4	0.03	9.7e-01	IL12B PNMT PPP5C TNFSF15
Wheeze or whistling in the chest in last year	2.21	4	3	6.7	0.49	4.1e-01	KIAA1109 LRRC32 PNMT SMAD3
Trunk predicted mass	2.18	14	10	22.2	0.52	4.1e-02	AC074117.10 ADO CARD9 HINT1 MTMR3 NFATC2IP PDE4A PDLIM4 PLCL1 RFT1 RP11-373D23.3 SLC22A5 ZBTB38 ZMIZ1
Trunk fat-free mass	2.17	14	10	22.2	0.52	4.0e-02	AC074117.10 ADO CARD9 HINT1 MTMR3 NFATC2IP PDE4A PDLIM4 PLCL1 RFT1 RP11-373D23.3 SLC22A5 ZBTB38 ZMIZ1
Whole body fat-free mass	2.17	14	9	20.0	0.54	3.2e-02	AC074117.10 ADO CARD9 HINT1 MTMR3 NFATC2IP PDE4A PDLIM4 PLCL1 RFT1 RP11-373D23.3 SLC22A5 ZBTB38 ZMIZ1
Blood Platelet Count	2.15	27	17	37.8	-0.23	2.1e-01	AC010883.5 AC074117.10 ADO ATG16L1 C11orf30 DOCK8 FUT2 HEATR3 HINT1 IGHEP2 MST1 MTMR3 NDFIP1 PDLIM4 PNMT POLR2E PPP1R14B PTGER4 RMI2 RP11-373D23.3 RP11-429P3.3 RP11-464F9.22 RPL23AP79 RSPO3 SLC22A5 STMN3 ZMIZ1
Whole body water mass	2.15	14	9	20.0	0.54	3.2e-02	AC074117.10 ADO CARD9 HINT1 MTMR3 NFATC2IP PDE4A PDLIM4 PLCL1 RFT1 RP11-373D23.3 SLC22A5 ZBTB38 ZMIZ1
Heel T-Score	2.14	13	7	15.6	-0.17	5.9e-01	AC010883.5 CCDC116 DOCK8 MMP9 MST1 POLR2E PPP1R14B RFT1 RPL23AP79 RSPO3 SLC22A5 TSPAN14 ZBTB38
Primary Biliary Cirrhosis	2.13	4	3	6.7	1.00	1.8e-03	PNMT PPP1R14B RMI2 SYNGR1
Number of self-reported non-cancer illnesses	2.13	5	1	2.2	0.64	2.4e-01	AC074117.10 FUT2 LRRC32 SLC22A5 STMN3
Leg fat-free mass (left)	2.12	10	7	15.6	0.61	3.7e-02	AC074117.10 ADO HINT1 NFATC2IP PDE4A PDLIM4 PLCL1 SLC22A5 ZBTB38 ZMIZ1
Leg predicted mass (left)	2.12	10	7	15.6	0.66	1.9e-02	AC074117.10 ADO HINT1 NFATC2IP PDE4A PDLIM4 PLCL1 PPP1R14B SLC22A5 ZBTB38
Basal metabolic rate	2.12	14	7	15.6	0.55	2.8e-02	AC074117.10 ADO CARD9 HINT1 MTMR3 NFATC2IP PDE4A PDLIM4 PLCL1 RFT1 RP11-373D23.3 SLC22A5 ZBTB38 ZMIZ1
Arm predicted mass (left)	2.10	12	9	20.0	0.46	9.5e-02	AC074117.10 CARD9 HINT1 MTMR3 NFATC2IP PDE4A PDLIM4 PLCL1 RP11-373D23.3 SLC22A5 ZBTB38 ZMIZ1
Leg fat-free mass (right)	2.08	10	7	15.6	0.70	1.1e-02	AC074117.10 ADO HINT1 MTMR3 NFATC2IP PDE4A PDLIM4 PLCL1 SLC22A5 ZBTB38
Leg predicted mass (right)	2.08	10	7	15.6	0.70	1.1e-02	AC074117.10 ADO HINT1 MTMR3 NFATC2IP PDE4A PDLIM4 PLCL1 SLC22A5 ZBTB38
Arm fat-free mass (left)	2.07	12	10	22.2	0.46	9.6e-02	AC074117.10 CARD9 HINT1 MTMR3 NFATC2IP PDE4A PDLIM4 PLCL1 RP11-373D23.3 SLC22A5 ZBTB38 ZMIZ1
Arm predicted mass (right)	2.05	11	9	20.0	0.43	1.4e-01	AC074117.10 CARD9 HINT1 NFATC2IP PDE4A PDLIM4 PLCL1 RP11-373D23.3 SLC22A5 ZBTB38 ZMIZ1
Arm fat-free mass (right)	2.04	11	9	20.0	0.54	5.8e-02	AC074117.10 CARD9 HINT1 MTMR3 NFATC2IP PDE4A PDLIM4 PLCL1 RP11-373D23.3 SLC22A5 ZBTB38
Pulse rate, automated reading	2.03	5	4	8.9	-0.23	7.1e-01	AC074117.10 C11orf30 GIGYF1 MST1 ZBTB38
Lupus	2.00	2	1	2.2	0.00	1.0e+00	CCDC116 DCLRE1B
Medication: Seretide 50 evohaler	1.99	3	0	0.0	0.08	9.2e-01	PDLIM4 SLC22A5 SMAD3
Fasting Glucose	1.94	2	1	2.2	0.00	1.0e+00	AC074117.10 RP11-373D23.3
High cholesterol (Self-reported)	1.92	2	2	4.4	0.00	1.0e+00	AC074117.10 FUT2
Heel bone mineral density (BMD) T-score, automated (left)	1.89	2	1	2.2	0.00	1.0e+00	MST1 RSPO3
Forced expiratory volume in 1-second (FEV1), predicted	1.88	5	2	4.4	0.90	1.4e-02	PDE4A PDLIM4 RFT1 SLC22A5 ZBTB38
Diabetes diagnosed by doctor	1.88	2	2	4.4	0.00	1.0e+00	AC010883.5 AC074117.10
Diabetes (self-reported)	1.87	2	1	2.2	0.00	1.0e+00	AC010883.5 AC074117.10
Weight	1.87	10	6	13.3	0.53	7.4e-02	AC074117.10 ADCY3 HINT1 MST1 NFATC2IP PDE4A PDLIM4 PPP1R14B SLC22A5 ZBTB38
Type 2 Diabetes (T2D) (2018)	1.86	3	2	4.4	0.00	1.0e+00	AC010883.5 AC074117.10 STMN3
Hand grip strength (right)	1.85	7	6	13.3	0.47	1.7e-01	ADCY3 HINT1 NFATC2IP PDLIM4 RFT1 SLC22A5 ZBTB38
Heel bone mineral density (BMD) T-score, automated (right)	1.83	3	1	2.2	0.00	1.0e+00	MST1 RSPO3 ZBTB38
Gout (self-reported)	1.83	2	1	2.2	0.00	1.0e+00	AC074117.10 PPP1R14B
Lung FEV1/FVC ratio	1.80	11	6	13.3	0.41	1.3e-01	AC010883.5 ADCY3 ADO FUT2 IL18R1 PNMT RP11-464F9.22 SLC22A5 SMAD3 TSPAN14 ZBTB38
Hand grip strength (left)	1.78	6	5	11.1	0.71	4.9e-02	ADCY3 HINT1 PDLIM4 RFT1 SLC22A5 ZBTB38
Long-standing illness, disability or infirmity	1.77	1	0	0.0	0.00	1.0e+00	DCLRE1B
Breast Cancer	1.73	5	4	8.9	-0.25	6.3e-01	ADCY3 DCLRE1B PARK7 SLC22A5 ZBTB38
Medication: Metformin	1.73	2	1	2.2	0.00	1.0e+00	AC010883.5 AC074117.10
Diabetes (father)	1.73	1	1	2.2	0.00	1.0e+00	AC010883.5
Taking other prescription medications	1.72	3	0	0.0	0.00	1.0e+00	DCLRE1B PPP1R14B RNASET2
Trunk fat mass	1.67	5	5	11.1	0.58	3.1e-01	ADCY3 HINT1 MST1 NFATC2IP ZBTB38
Arm fat percentage (right)	1.65	4	3	6.7	0.60	4.0e-01	ADCY3 GALC MST1 NFATC2IP
Birth weight of first child	1.64	2	1	2.2	0.00	1.0e+00	TSPAN14 ZBTB38
Pulse rate	1.63	3	2	4.4	0.00	1.0e+00	AC074117.10 GIGYF1 ZBTB38
Exposure to tobacco smoke outside home	1.63	1	0	0.0	0.00	1.0e+00	RP11-464F9.22
Alcohol intake frequency.	1.63	4	3	6.7	-0.31	6.9e-01	AC074117.10 FUT2 MST1 NFATC2IP
Arm fat mass (right)	1.61	6	5	11.1	0.61	2.0e-01	ADCY3 GALC HINT1 MST1 NFATC2IP ZBTB38
Whole body fat mass	1.61	5	5	11.1	0.58	3.1e-01	ADCY3 HINT1 MST1 NFATC2IP ZBTB38
Arm fat percentage (left)	1.61	4	3	6.7	0.59	4.1e-01	ADCY3 GALC MST1 NFATC2IP
Cardiovascular Disease	1.58	7	3	6.7	0.63	1.3e-01	AC074117.10 ADO ATG16L1 FUT2 NFATC2IP SLC22A5 STMN3
Hip circumference	1.58	6	4	8.9	0.75	8.7e-02	ADCY3 HINT1 NFATC2IP PDE4A PPP1R14B ZBTB38
BMI	1.57	10	6	13.3	0.54	1.1e-01	ADCY3 FIBP GALC GPR65 HINT1 MST1 NFATC2IP PLCL1 PPP1R14B RFT1
Arm fat mass (left)	1.57	6	5	11.1	0.61	2.0e-01	ADCY3 GALC HINT1 MST1 NFATC2IP ZBTB38
Medication: Bendroflumethiazide	1.57	2	1	2.2	0.00	1.0e+00	FUT2 PDLIM4
Medication: Cholesterol lowering	1.55	2	2	4.4	0.00	1.0e+00	AC074117.10 FUT2
Diastolic blood pressure, automated reading	1.54	7	5	11.1	0.12	7.9e-01	ADO DNAJC28 ERAP2 GIGYF1 MST1 PDLIM4 STMN3
Number of treatments/medications taken	1.53	2	0	0.0	0.00	1.0e+00	AC074117.10 DCLRE1B
Trunk fat percentage	1.52	4	4	8.9	0.57	4.3e-01	ADCY3 MST1 NFATC2IP ZBTB38
Birth weight	1.52	3	1	2.2	0.00	1.0e+00	FUT2 RFT1 RSPO3
HDL Cholesterol	1.51	2	2	4.4	0.00	1.0e+00	CCDC116 PNMT
Leg fat mass (left)	1.51	5	4	8.9	0.57	3.2e-01	ADCY3 HINT1 MST1 NFATC2IP ZBTB38
Body fat percentage	1.50	4	3	6.7	0.60	4.0e-01	ADCY3 MST1 NFATC2IP ZBTB38
Leg fat mass (right)	1.50	5	4	8.9	0.57	3.2e-01	ADCY3 HINT1 MST1 NFATC2IP ZBTB38
Medication: Atorvastatin	1.50	1	1	2.2	0.00	1.0e+00	AC074117.10
Medication: Allopurinol	1.48	2	1	2.2	0.00	1.0e+00	AC074117.10 RP11-373D23.3
Leg fat percentage (left)	1.48	3	3	6.7	0.00	1.0e+00	ADCY3 MST1 NFATC2IP
Waist circumference	1.47	6	3	6.7	0.77	7.1e-02	ADCY3 HINT1 NFATC2IP RSPO3 ZBTB38 ZMIZ1
Illnesses of father: Heart disease	1.47	1	0	0.0	0.00	1.0e+00	SMAD3
Alcohol intake versus 10 years previously	1.46	3	1	2.2	0.00	1.0e+00	AC074117.10 FUT2 MST1
Medication: Simvastatin	1.44	2	1	2.2	0.00	1.0e+00	AC074117.10 FUT2
Medication for cholesterol, blood pressure or diabetes	1.42	1	0	0.0	0.00	1.0e+00	FUT2
Vascular/heart problems diagnosed by doctor	1.42	4	3	6.7	-0.11	8.3e-01	ADO FUT2 PDLIM4 SLC22A5
Body Mass Index (BMI) (2010)	1.41	2	2	4.4	0.00	1.0e+00	ADCY3 NFATC2IP
Body mass index (BMI)	1.41	6	3	6.7	0.55	2.6e-01	ADCY3 GALC MST1 NFATC2IP PLCL1 RFT1
Leg fat percentage (right)	1.41	3	3	6.7	0.00	1.0e+00	ADCY3 MST1 NFATC2IP
Fed-up feelings	1.40	2	1	2.2	0.00	1.0e+00	MST1 PPP1R14B
Osteoporosis (self-reported)	1.40	1	0	0.0	0.00	1.0e+00	PPP1R14B
Number of operations (self-reported)	1.40	2	0	0.0	0.00	1.0e+00	MTMR3 PARK7
Prostate Cancer	1.39	1	1	2.2	0.00	1.0e+00	C11orf30
Blood Red Count	1.39	17	11	24.4	0.28	2.4e-01	DOCK8 GIGYF1 GPX4 IGHEP2 MST1 NDFIP1 NFATC2IP PLCL1 PNMT POLR2E PPP5C PTGER4 PTPN2 RP11-373D23.3 RSPO3 STMN3 ZBTB38
Shortness of breath walking on level ground	1.39	1	0	0.0	0.00	1.0e+00	LRRC32
Qualifications: College or University degree	1.37	3	2	4.4	0.00	1.0e+00	MST1 NFATC2IP STMN3
High blood pressure	1.36	4	2	4.4	0.25	6.8e-01	ADO FUT2 PDLIM4 SLC22A5
Ever had prostate specific antigen (PSA) test	1.36	1	0	0.0	0.00	1.0e+00	ZBTB38
Frequency of tiredness / lethargy in last 2 weeks	1.34	1	0	0.0	0.00	1.0e+00	RP11-464F9.22
Lung FVC	1.33	10	7	15.6	-0.76	4.4e-03	CARD9 HINT1 NFATC2IP PARK7 PDLIM4 PNMT RP11-464F9.22 SLC22A5 STMN3 ZBTB38
Mouth/teeth dental problems: Dentures	1.33	3	1	2.2	0.00	1.0e+00	ADCY3 FUT2 PNMT
Hypertension (Self-reported)	1.31	4	3	6.7	0.20	7.5e-01	ADO FUT2 PDLIM4 SLC22A5
Forced expiratory volume in 1-second (FEV1), Best measure	1.30	8	2	4.4	0.64	4.5e-02	ADCY3 ADO ICOSLG MTMR3 RFT1 SLC22A5 STMN3 ZBTB38
Cholesterol lowering medication	1.30	2	1	2.2	0.00	1.0e+00	AC074117.10 FUT2
Fractured/broken bones in last 5 years	1.28	1	1	2.2	0.00	1.0e+00	RSPO3
Forced expiratory volume in 1-second (FEV1)	1.27	6	3	6.7	0.56	1.5e-01	ADCY3 MTMR3 RFT1 SLC22A5 STMN3 ZBTB38
Average weekly spirits intake	1.26	2	0	0.0	0.00	1.0e+00	FUT2 MST1
Age when periods started (menarche)	1.25	3	1	2.2	0.00	1.0e+00	ADCY3 C11orf30 FUT2
Had menopause	1.24	1	1	2.2	0.00	1.0e+00	AC074117.10
Forced vital capacity (FVC)	1.24	6	4	8.9	0.24	6.4e-01	ADCY3 MMP9 MTMR3 RFT1 STMN3 ZBTB38
Mouth/teeth dental problems	1.23	1	0	0.0	0.00	1.0e+00	FUT2
Medication for cholesterol	1.21	1	0	0.0	0.00	1.0e+00	FUT2
Worry (Nagel 2018)	1.20	2	0	0.0	0.00	1.0e+00	CD40 MTMR3
Systolic Blood Pressure	1.20	14	6	13.3	0.14	6.2e-01	AC074117.10 ADCY3 ADO C11orf30 CCDC116 CUL2 DOCK8 ERAP2 FUT2 PRKAA1 RP11-464F9.22 SMAD3 STMN3 TSPAN14
Forced vital capacity (FVC), Best measure	1.20	5	4	8.9	0.35	5.7e-01	ADCY3 MTMR3 RFT1 STMN3 ZBTB38
Medication: Blood pressure	1.20	2	0	0.0	0.00	1.0e+00	PDLIM4 SLC22A5
Intelligence (Savage-Jansen 2018)	1.19	2	2	4.4	0.00	1.0e+00	MST1 NFATC2IP
Bipolar Disorder or Schizophrenia	1.18	3	0	0.0	0.00	1.0e+00	CD40 FUT2 GIGYF1
Depressed Affect (Nagel 2018)	1.18	2	1	2.2	0.00	1.0e+00	CD40 MST1
Current tobacco smoking	1.18	1	1	2.2	0.00	1.0e+00	STMN3
Seen doctor (GP) for nerves, anxiety, tension or depression	1.18	1	0	0.0	0.00	1.0e+00	MIER1
Hair/balding pattern: Pattern 4	1.17	1	1	2.2	0.00	1.0e+00	ZBTB38
Peak expiratory flow (PEF)	1.16	2	1	2.2	0.00	1.0e+00	AC010883.5 FUT2
Neuroticism (Nagel 2018)	1.15	2	1	2.2	0.00	1.0e+00	CD40 RNASET2
Schizophrenia (2018)	1.14	1	0	0.0	0.00	1.0e+00	GIGYF1
Impedance of arm (right)	1.14	6	4	8.9	0.88	2.0e-02	AC074117.10 LRRC32 PLCL1 RFT1 RP11-373D23.3 SMAD3
Impedance of leg (left)	1.13	10	5	11.1	-0.10	7.8e-01	AC010883.5 AC074117.10 ADCY3 CCDC116 FIBP HEATR3 HINT1 NFATC2IP PLCL1 RP11-429P3.3
Waist Hip Ratio (WHR)	1.12	5	1	2.2	0.56	3.3e-01	AC010883.5 FUT2 PPP1R14B RSPO3 ZBTB38
Qualifications: A levels/AS levels or equivalent	1.12	1	1	2.2	0.00	1.0e+00	MST1
Schizophrenia (2014)	1.11	3	0	0.0	0.00	1.0e+00	GIGYF1 LACC1 PLCL1
Relative age of first facial hair	1.11	2	0	0.0	0.00	1.0e+00	CUL2 ZBTB38
Fluid intelligence score	1.11	2	1	2.2	0.00	1.0e+00	MST1 NFATC2IP
Impedance of arm (left)	1.11	5	3	6.7	0.89	4.5e-02	AC074117.10 LRRC32 PLCL1 RP11-373D23.3 SMAD3
Suffer from 'nerves'	1.11	1	1	2.2	0.00	1.0e+00	NFATC2IP
Overall health rating	1.11	1	1	2.2	0.00	1.0e+00	MST1
Neuroticism score	1.10	2	0	0.0	0.00	1.0e+00	AC010883.5 CD40
Systolic blood pressure, automated reading	1.09	1	1	2.2	0.00	1.0e+00	ADO
Smoking status: Current	1.09	1	0	0.0	0.00	1.0e+00	STMN3
Impedance of leg (right)	1.08	9	5	11.1	0.00	1.0e+00	AC010883.5 AC074117.10 ADCY3 CCDC116 HEATR3 HINT1 NFATC2IP PLCL1 RP11-429P3.3
Verbal and Numeric Reasoning (VNR)	1.07	3	2	4.4	0.00	1.0e+00	ADCY3 MST1 NFATC2IP
Neuroticism	1.07	1	1	2.2	0.00	1.0e+00	CD40
Irritability	1.07	2	0	0.0	0.00	1.0e+00	AC010883.5 ERAP2
Impedance of whole body	1.06	9	4	8.9	0.62	7.6e-02	AC010883.5 AC074117.10 ADCY3 HEATR3 HINT1 PLCL1 RP11-373D23.3 RP11-429P3.3 ZMIZ1
Qualifications: nursing, teaching	1.05	1	0	0.0	0.00	1.0e+00	MST1
Chronotype (morning person)	1.04	2	0	0.0	0.00	1.0e+00	MMP9 PLCL1
Smoking Status	1.02	1	0	0.0	0.00	1.0e+00	PPP1R14B
Age at First Birth	1.01	1	0	0.0	0.00	1.0e+00	MST1
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.01	2	0	0.0	0.00	1.0e+00	PNMT STMN3
LDL Cholesterol	0.99	1	1	2.2	0.00	1.0e+00	FUT2
Nervous feelings	0.97	1	0	0.0	0.00	1.0e+00	MTMR3
Qualifications: None of the above	0.89	3	1	2.2	0.00	1.0e+00	MST1 NFATC2IP RFT1
Reaction Time	0.88	1	0	0.0	0.00	1.0e+00	ADCY3
Mean time to correctly identify matches	0.87	1	0	0.0	0.00	1.0e+00	ADCY3
Hair Pigment	0.44	9	8	17.8	0.56	1.1e-01	AC010883.5 AC074117.10 ADAM15 ADCY3 CUL2 DOCK8 GIGYF1 SYNGR1 ZBTB38
Tanning	0.28	4	3	6.7	-0.97	3.4e-02	AC074117.10 ADCY3 ADO IL18R1

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Whole Blood	26	1.31	2.8
The Cancer Genome Atlas	Rectum Adenocarcinoma	8	1.15	2.7
GTEx	Ovary	13	1.43	2.6
NTR	Blood	31	1.29	2.6
GTEx	Esophagus Mucosa	37	1.11	2.5
GTEx	Prostate	10	1.20	2.5
GTEx	Spleen	15	1.06	2.5
GTEx	Brain Cerebellar Hemisphere	18	1.21	2.4
GTEx	Brain Cortex	12	1.16	2.4
GTEx	Brain Hypothalamus	6	1.02	2.4
GTEx	Brain Putamen basal ganglia	7	1.12	2.4
GTEx	Heart Atrial Appendage	15	0.95	2.4
GTEx	Lung	34	1.19	2.4
GTEx	Skin Not Sun Exposed Suprapubic	27	1.10	2.4
GTEx	Vagina	8	1.26	2.4
The Cancer Genome Atlas	Lung Adenocarcinoma	28	0.95	2.4
GTEx	Brain Caudate basal ganglia	13	1.41	2.3
GTEx	Brain Cerebellum	20	1.01	2.3
GTEx	Brain Nucleus accumbens basal ganglia	12	1.39	2.3
GTEx	Esophagus Gastroesophageal Junction	21	1.45	2.3
GTEx	Pituitary	12	1.08	2.3
GTEx	Skin Sun Exposed Lower leg	30	0.83	2.3
GTEx	Stomach	15	1.03	2.3
GTEx	Uterus	5	0.88	2.3
YFS	Blood	42	0.91	2.3
The Cancer Genome Atlas	Colon Adenocarcinoma	17	0.82	2.3
The Cancer Genome Atlas	Skin Cutaneous Melanoma	6	1.12	2.3
GTEx	Adipose Subcutaneous	25	0.72	2.2
GTEx	Adipose Visceral Omentum	15	0.74	2.2
GTEx	Adrenal Gland	11	0.76	2.2
GTEx	Artery Coronary	14	1.19	2.2
GTEx	Artery Tibial	36	0.96	2.2
GTEx	Brain Frontal Cortex BA9	7	0.76	2.2
GTEx	Brain Hippocampus	5	0.95	2.2
GTEx	Breast Mammary Tissue (Male)	11	0.92	2.2
GTEx	Cells Transformed fibroblasts	35	0.83	2.2
GTEx	Colon Sigmoid	12	0.82	2.2
GTEx	Colon Transverse	20	0.97	2.2
GTEx	Esophagus Muscularis	29	0.90	2.2
GTEx	Heart Left Ventricle	12	0.78	2.2
GTEx	Muscle Skeletal	24	0.83	2.2
GTEx	Nerve Tibial	42	0.97	2.2
GTEx	Testis	27	0.86	2.2
GTEx	Thyroid	33	0.83	2.2
METSIM	Adipose	44	0.96	2.2
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	9	0.82	2.2
The Cancer Genome Atlas	Glioblastoma Multiforme	7	0.68	2.2
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	17	0.62	2.2
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	15	0.73	2.2
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	22	0.88	2.2
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	11	0.66	2.2
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	10	0.76	2.2
The Cancer Genome Atlas	Stomach Adenocarcinoma	13	0.77	2.2
The Cancer Genome Atlas	Testicular Germ Cell Tumors	9	0.70	2.2
GTEx	Artery Aorta	23	0.77	2.1
GTEx	Breast Mammary Tissue	17	0.86	2.1
GTEx	Breast Mammary Tissue (Female)	11	0.67	2.1
GTEx	Cells EBV-transformed lymphocytes	9	0.63	2.1
GTEx	Liver	3	0.42	2.1
GTEx	Pancreas	10	0.61	2.1
GTEx	Small Intestine Terminal Ileum	4	0.88	2.1
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	12	0.73	2.1
The Cancer Genome Atlas	Breast Invasive Carcinoma	36	0.82	2.1
The Cancer Genome Atlas	Brain Lower Grade Glioma	35	0.81	2.1
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	9	0.81	2.1
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	11	0.69	2.1
The Cancer Genome Atlas	Soft Tissue Sarcoma	5	0.47	2.1
The Cancer Genome Atlas	Thyroid Carcinoma	42	0.82	2.1
ROSMAP	Brain Pre-frontal Cortex	31	0.71	2.0
CommonMind	Brain Pre-frontal Cortex	36	0.67	2.0
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	30	0.73	2.0
The Cancer Genome Atlas	Prostate Adenocarcinoma	33	0.71	2.0
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	3	0.59	2.0
The Cancer Genome Atlas	Esophageal Carcinoma	3	0.44	1.9